Interpace Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $18.4M | $2.3M |
| FY2020 | — | $-10.9M | $2.8M |
| FY2021 | — | $-42.4M | $2.7M |
| FY2022 | — | $-58.1M | $4.8M |
| FY2023 | — | $-57.4M | $5.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $18.4M | $2.3M |
| FY2020 | — | $-10.9M | $2.8M |
| FY2021 | — | $-42.4M | $2.7M |
| FY2022 | — | $-58.1M | $4.8M |
| FY2023 | — | $-57.4M | $5.6M |